Treatment of Uncontrolled Diabetes Mellitus

Initial Assessment and Severity Stratification

For patients with uncontrolled type 2 diabetes, the American Diabetes Association recommends immediately intensifying therapy by adding a second agent to metformin if HbA1c remains above target after 3 months of monotherapy, or starting insulin therapy if blood glucose is ≥300 mg/dL or HbA1c ≥10%, especially if symptomatic 1, 2
The American Diabetes Association suggests determining the degree of hyperglycemia to guide treatment intensity, with severe hyperglycemia (blood glucose ≥300 mg/dL or HbA1c ≥10%) requiring immediate insulin therapy, particularly if catabolic features or symptoms are present 1, 3, 4
For moderate hyperglycemia (HbA1c 9-10%), the American College of Physicians recommends considering initial dual-combination therapy rather than sequential addition to achieve faster glycemic control 5, 6, 7
For mild-moderate hyperglycemia (HbA1c 7-9%), the American Diabetes Association recommends adding a second agent to existing metformin therapy 6, 1

If a patient is not currently on metformin, the American Diabetes Association recommends starting metformin immediately (unless contraindicated) along with lifestyle modifications 6, 1, 8, 9
Metformin reduces cardiovascular events and mortality, is inexpensive, and has established safety, according to the American College of Physicians 6
For patients with established cardiovascular disease, high cardiovascular risk, chronic kidney disease, or heart failure, the American Heart Association prioritizes SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit 1, 2
GLP-1 receptor agonists are preferred over insulin when possible, causing weight loss, lowering hypoglycemia risk, and providing cardiovascular benefits, according to the American Diabetes Association 1, 2

The American Diabetes Association recommends initiating basal insulin at 10 units or 0.1-0.2 units/kg body weight 7, 10
Continue metformin (and possibly one additional agent) when starting basal insulin, according to the American College of Physicians 7, 10
For severe hyperglycemia with symptoms (blood glucose ≥300-350 mg/dL, HbA1c 10-12%), consider basal plus mealtime insulin from the outset 5, 7, 10

The American Diabetes Association recommends not delaying treatment intensification, with immediate addition of a second agent if monotherapy at maximum tolerated dose fails to achieve HbA1c target over 3 months 6, 7
Reevaluate medication regimen every 3-6 months, according to the American Diabetes Association 1, 2
Dual therapy with metformin and sulfonylurea alone is often insufficient for severe hyperglycemia, indicating significant insulin deficiency requiring more potent intervention, according to the American College of Physicians 2

Implement frequent home blood glucose monitoring for uncontrolled hyperglycemia, according to the American Diabetes Association 2
Check HbA1c every 3 months to assess long-term glycemic control, recommends the American Diabetes Association 2
Evaluate for diabetes complications and provide appropriate preventive care, according to the American Diabetes Association 2

NPH insulin is an acceptable intermediate-acting basal insulin option that provides relatively uniform coverage throughout the day and night, mainly suppressing hepatic glucose production between meals and during sleep, according to the American Diabetes Association guidelines 11
Long-acting insulin analogs (glargine or detemir) are associated with modestly less overnight hypoglycemia and possibly slightly less weight gain with detemir, compared to NPH insulin 11

The American College of Physicians recommends prescribing glucagon and educating the patient and close contacts on recognition and treatment of hypoglycemia when initiating insulin therapy 12
Patients should be instructed to treat hypoglycemia (blood glucose <70 mg/dL) with 15-20 grams of rapid-acting carbohydrate, recheck in 15 minutes, and repeat if needed, as advised by the American College of Physicians 12
Situations increasing hypoglycemia risk include fasting for procedures, during/after exercise, during sleep, and with alcohol consumption, according to the American College of Physicians guidelines 12

A reasonable initial target HbA1c is <8%, then reassess based on patient factors, to avoid increasing hypoglycemia risk without additional cardiovascular benefits, as recommended by the American College of Physicians 13
Diabetes self-management education and lifestyle modifications remain foundational even when initiating insulin therapy, according to the American College of Physicians guidelines 13